{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:04:45Z","timestamp":1774922685770,"version":"3.50.1"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.phrs.2022.106342","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T11:55:14Z","timestamp":1656935714000},"page":"106342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Omega-3 and cardiovascular prevention \u2013 Is this still a choice?"],"prefix":"10.1016","volume":"182","author":[{"given":"Massimiliano","family":"Ruscica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Carugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip C.","family":"Calder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.phrs.2022.106342_bib1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"E. Pravastatin or Atorvastatin, I. Infection Therapy-Thrombolysis in Myocardial Infarction, Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.phrs.2022.106342_bib2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"I. Treating to new targets, Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106342_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib5","first-page":"109","article-title":"Editorial: omega-3 fatty acids: new studies, new data, new questions","volume":"24","author":"Calder","year":"2021","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4187\/respcare.06965","article-title":"Immunonutrition for adults with ARDS: results from a cochrane systematic review and meta-analysis","volume":"65","author":"Dushianthan","year":"2020","journal-title":"Respir. Care"},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/md19060306","article-title":"Advances in technologies for highly active omega-3 fatty acids from krill oil: clinical applications","volume":"19","author":"Colletti","year":"2021","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S0029665117003950","article-title":"Very long-chain n-3 fatty acids and human health: fact, fiction and the future","volume":"77","author":"Calder","year":"2018","journal-title":"Proc. Nutr. Soc."},{"issue":"10","key":"10.1016\/j.phrs.2022.106342_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ejlt.201400025","article-title":"Very long chain omega-3 (n-3) fatty acids and human health","volume":"116","author":"Calder","year":"2014","journal-title":"Eur. J. Lipid Sci. Technol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cell.2010.07.041","article-title":"GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects","volume":"142","author":"Oh","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13075-022-02781-2","article-title":"Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis","volume":"24","author":"Sigaux","year":"2022","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib12","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/ajcn\/nqab427","article-title":"Dietary intake and plasma concentrations of PUFAs in childhood and adolescence in relation to asthma and lung function up to adulthood","volume":"115","author":"Ekstrom","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"issue":"10","key":"10.1016\/j.phrs.2022.106342_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/nutrit\/nuz098","article-title":"Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trials","volume":"78","author":"Chen","year":"2020","journal-title":"Nutr. Rev."},{"issue":"13","key":"10.1016\/j.phrs.2022.106342_bib14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.2022.2027","article-title":"Effect of long-term supplementation with marine omega-3 fatty acids vs placebo on risk of depression","volume":"327","author":"Chen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2022.106342_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.biochi.2020.08.015","article-title":"Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake","volume":"178","author":"Calder","year":"2020","journal-title":"Biochimie"},{"issue":"9567","key":"10.1016\/j.phrs.2022.106342_bib16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.phrs.2022.106342_bib18","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/eurheartj\/ehz778","article-title":"Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics","volume":"41","author":"Boden","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106342_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105060","article-title":"Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials","volume":"160","author":"Casula","year":"2020","journal-title":"Pharm. Res."},{"issue":"6 Suppl","key":"10.1016\/j.phrs.2022.106342_bib20","doi-asserted-by":"crossref","first-page":"1321S","DOI":"10.1093\/ajcn\/61.6.1321S","article-title":"Mediterranean diet and public health: personal reflections","volume":"61","author":"Keys","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.CIR.59.1.1","article-title":"Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes","volume":"59","author":"Turpeinen","year":"1979","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M13-1788","article-title":"Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis","volume":"160","author":"Chowdhury","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2022.106342_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2019.11.018","article-title":"Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects","volume":"292","author":"Marangoni","year":"2020","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ajcn\/nqz349","article-title":"Dietary intake and biomarkers of linoleic acid and mortality: systematic review and meta-analysis of prospective cohort studies.","volume":"112","author":"Li","year":"2020","journal-title":"Am. J. Clin. Nutr."},{"issue":"21","key":"10.1016\/j.phrs.2022.106342_bib25","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/CIRCULATIONAHA.118.038908","article-title":"Aging research in genomic epidemiology fatty, c. outcomes research, biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality","volume":"139","author":"Marklund","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.plipres.2008.03.003","article-title":"Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake","volume":"47","author":"Hodson","year":"2008","journal-title":"Prog. Lipid Res."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/ajcn\/77.4.796","article-title":"Adipose tissue n-6 fatty acids and acute myocardial infarction in a population consuming a diet high in polyunsaturated fatty acids","volume":"77","author":"Kark","year":"2003","journal-title":"Am. J. Clin. Nutr."},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jada.2006.11.008","article-title":"Intake and adipose tissue composition of fatty acids and risk of myocardial infarction in a male Portuguese community sample","volume":"107","author":"Lopes","year":"2007","journal-title":"J. Am. Diet. Assoc."},{"issue":"8","key":"10.1016\/j.phrs.2022.106342_bib29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/sj.ejcn.1601064","article-title":"Adipose tissue fatty acids and risk of myocardial infarction -- a case-control study","volume":"54","author":"Pedersen","year":"2000","journal-title":"Eur. J. Clin. Nutr."},{"issue":"7","key":"10.1016\/j.phrs.2022.106342_bib30","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00394-021-02526-y","article-title":"Linoleic acid in adipose tissue and the risk of myocardial infarction: a case-cohort study","volume":"60","author":"Nielsen","year":"2021","journal-title":"Eur. J. Nutr."},{"issue":"7","key":"10.1016\/j.phrs.2022.106342_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-158-7-201304020-00003","article-title":"Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study","volume":"158","author":"Mozaffarian","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jacl.2020.08.010","article-title":"Corrigendum to Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: the Framingham heart study","volume":"14","author":"Harris","year":"2020","journal-title":"J. Clin. Lipido"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ypmed.2004.02.030","article-title":"Schacky, The Omega-3 Index: a new risk factor for death from coronary heart disease?","volume":"39","author":"Harris","year":"2004","journal-title":"Prev. Med."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005444","article-title":"Red blood cell fatty acid patterns and acute coronary syndrome","volume":"4","author":"Shearer","year":"2009","journal-title":"PLOS One"},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib35","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.atherosclerosis.2015.03.043","article-title":"Red blood cell fatty acids and biomarkers of inflammation: a cross-sectional study in a community-based cohort","volume":"240","author":"Fontes","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib36","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/ajcn\/nqab195","article-title":"Using an erythrocyte fatty acid fingerprint to predict risk of all-cause mortality: the Framingham offspring cohort","volume":"114","author":"McBurney","year":"2021","journal-title":"Am. J. Clin. Nutr."},{"issue":"9","key":"10.1016\/j.phrs.2022.106342_bib37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/ajcn\/28.9.958","article-title":"Fatty acid composition of the plasma lipids in Greenland Eskimos","volume":"28","author":"Dyerberg","year":"1975","journal-title":"Am. J. Clin. Nutr."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ije\/17.3.514","article-title":"Mortality from ischaemic heart disease and cerebrovascular disease in Greenland","volume":"17","author":"Bjerregaard","year":"1988","journal-title":"Int. J. Epidemiol."},{"issue":"8852","key":"10.1016\/j.phrs.2022.106342_bib39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0140-6736(93)92413-N","article-title":"Atherosclerosis in Alaska natives and non-natives","volume":"341","author":"Newman","year":"1993","journal-title":"Lancet"},{"issue":"7710","key":"10.1016\/j.phrs.2022.106342_bib40","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0140-6736(71)91658-8","article-title":"Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos","volume":"1","author":"Bang","year":"1971","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib41","doi-asserted-by":"crossref","first-page":"592S","DOI":"10.3945\/jn.111.155259","article-title":"Mechanisms of action of (n-3) fatty acids","volume":"142","author":"Calder","year":"2012","journal-title":"J. Nutr."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","article-title":"Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?","volume":"75","author":"Calder","year":"2013","journal-title":"Br. J. Clin. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib43","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib44","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbalip.2011.10.011","article-title":"Fish oil -- how does it reduce plasma triglycerides?","volume":"1821","author":"Shearer","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.phrs.2022.106342_bib46","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1210\/jc.2016-2217","article-title":"omega-3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia","volume":"101","author":"Chan","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2022.106342_bib47","first-page":"822","article-title":"Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?","volume":"129","author":"Nelson","year":"2017"},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143861","article-title":"An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides","volume":"131","author":"Grevengoed","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.phrs.2022.106342_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025071","article-title":"Omega-3 polyunsaturated fatty acids intake and blood pressure: a dose-response meta-analysis of randomized controlled trials","volume":"11","author":"Zhang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.phrs.2022.106342_bib50","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1073\/pnas.95.8.4754","article-title":"Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats","volume":"95","author":"Suzuki","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10384-004-0116-5","article-title":"Effect of latanoprost 0.005% and brimonidine 0.2% on intraocular pressure after phacoemulsification and intraocular lens implantation surgery","volume":"48","author":"Erdogan","year":"2004","journal-title":"Jpn J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106342_bib52","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/hr.2017.72","article-title":"EPA:DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase- and COX-derived oxidative stress","volume":"40","author":"Niazi","year":"2017","journal-title":"Hypertens. Res."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041197","article-title":"PPAR agonists and metabolic syndrome: an established role?","volume":"19","author":"Botta","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.phrs.2022.106342_bib55","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Group","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jchf.2021.12.006","article-title":"Diabetes mellitus, race, and effects of omega-3 fatty acids on incidence of heart failure hospitalization","volume":"10","author":"Djousse","year":"2022","journal-title":"JACC Heart Fail."},{"issue":"9","key":"10.1016\/j.phrs.2022.106342_bib58","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/CIRCULATIONAHA.119.044645","article-title":"Supplementation with vitamin D and omega-3 fatty acids and incidence of heart failure hospitalization: VITAL-heart failure","volume":"141","author":"Djousse","year":"2020","journal-title":"Circulation"},{"issue":"9645","key":"10.1016\/j.phrs.2022.106342_bib59","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib60","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.phrs.2022.106342_bib61","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2022.106342_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024999","article-title":"Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT","volume":"11","author":"Selvaraj","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib64","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/ehjcvp\/pvaa118","article-title":"REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results","volume":"7","author":"Olshansky","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharm."},{"issue":"22","key":"10.1016\/j.phrs.2022.106342_bib65","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2022.106342_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2016.08.005","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies","volume":"253","author":"Ballantyne","year":"2016","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.phrs.2022.106342_bib68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jacc.2022.02.035","article-title":"Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction","volume":"79","author":"Gaba","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses","volume":"143","author":"Peterson","year":"2021","journal-title":"Circulation"},{"issue":"40","key":"10.1016\/j.phrs.2022.106342_bib70","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.phrs.2022.106342_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006981","article-title":"Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial","volume":"6","author":"Alfaddagh","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2022.106342_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105368","article-title":"Controversies about the cardiovascular effects of OM3FA. Did inappropriate placebos skew clinical trial results?","volume":"164","author":"do Vale","year":"2021","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMe1814004","article-title":"FISHing for the miracle of eicosapentaenoic acid","volume":"380","author":"Kastelein","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s13318-016-0398-2","article-title":"Systemic bioavailability and dose proportionality of omega-3 administered in free fatty acid form compared with ethyl ester form: results of a phase 1 study in healthy volunteers","volume":"42","author":"Offman","year":"2017","journal-title":"Eur. J. Drug Metab. Pharm."},{"issue":"22","key":"10.1016\/j.phrs.2022.106342_bib75","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2020.22387","article-title":"Effects of omega-3 fatty acids on major adverse cardiovascular events: what matters most: the drug, the dose, or the placebo?","volume":"324","author":"Sharma","year":"2020","journal-title":"JAMA"},{"issue":"Suppl. J.","key":"10.1016\/j.phrs.2022.106342_bib76","doi-asserted-by":"crossref","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","article-title":"Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies","volume":"22","author":"Olshansky","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"issue":"10","key":"10.1016\/j.phrs.2022.106342_bib77","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1161\/STROKEAHA.109.552802","article-title":"High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction","volume":"40","author":"Elkind","year":"2009","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib78","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib79","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2022.106342_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105812","article-title":"Lipoprotein(a): knowns, unknowns and uncertainties","volume":"173","author":"Ruscica","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106342_bib81","doi-asserted-by":"crossref","unstructured":"P.M. Ridker, N. Rifai, J. MacFadyen, R.J. Glynn, L. Jiao, P.G. Steg, M. Miller, E.A. Brinton, T.A. Jacobson, J.C. Tardif, C.M. Ballantyne, R.P. Mason, D.L. Bhatt, Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1beta, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy, Circulation (2022) 101161CIRCULATIONAHA122059410.","DOI":"10.1161\/CIRCULATIONAHA.122.059410"},{"issue":"47","key":"10.1016\/j.phrs.2022.106342_bib82","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur. Heart J."},{"issue":"47","key":"10.1016\/j.phrs.2022.106342_bib83","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1093\/eurheartj\/ehab760","article-title":"The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl","volume":"42","author":"Steg","year":"2021","journal-title":"Eur. Heart J."},{"issue":"47","key":"10.1016\/j.phrs.2022.106342_bib84","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1093\/eurheartj\/ehab643","article-title":"Investigating contrasting results in REDUCE-IT and STRENGTH: partial answers but questions remain","volume":"42","author":"Maki","year":"2021","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.phrs.2022.106342_bib85","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jacc.2015.07.055","article-title":"Saturated fats compared with unsaturated fats and sources of carbohydrates in relation to risk of coronary heart disease: a prospective cohort study","volume":"66","author":"Li","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib86","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/cvr\/cvz329","article-title":"Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography","volume":"116","author":"Lakshmanan","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib87","first-page":"1457","article-title":"Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with diabetes: a randomized, double-blind, placebo-controlled study","volume":"19","author":"Shaikh","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib88","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106342_bib89","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and Non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib91","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2022.106342_bib92","doi-asserted-by":"crossref","unstructured":"S.E. Nissen, A.M. Lincoff, K. Wolski, C.M. Ballantyne, J.J.P. Kastelein, P.M. Ridker, K.K. Ray, D.K. McGuire, D. Mozaffarian, W. Koenig, M.H. Davidson, M. Garcia, B.G. Katona, A. Himmelmann, L.E. Loss, M. Poole, V. Menon, S.J. Nicholls, Association Between Achieved omega-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial, JAMA Cardiol (2021).","DOI":"10.1001\/jamacardio.2021.1157"},{"key":"10.1016\/j.phrs.2022.106342_bib93","unstructured":"D.L. Bhatt, M. Miller, G. Steg, EPA levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial, 2020."},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.5876","article-title":"Relationships between plasma fatty acid composition and coronary artery disease","volume":"18","author":"Itakura","year":"2011","journal-title":"J. Atheroscler. Thromb."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib95","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/joim.13442","article-title":"Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial","volume":"291","author":"Myhre","year":"2022","journal-title":"J. Intern. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106342_bib96","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjmed.2021.03.014","article-title":"Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction","volume":"134","author":"Mason","year":"2021","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib97","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1038\/s41467-021-22370-2","article-title":"C. outcomes research, blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies","volume":"12","author":"Harris","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.phrs.2022.106342_bib98","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017401","article-title":"Plasma omega-3 fatty acids and the risk of cardiovascular events in patients after an acute coronary syndrome in MERLIN-TIMI 36","volume":"10","author":"Zelniker","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"22","key":"10.1016\/j.phrs.2022.106342_bib99","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.phrs.2022.106342_bib100","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib101","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.mayocp.2020.08.034","article-title":"Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials","volume":"96","author":"Bernasconi","year":"2021","journal-title":"Mayo Clin. Proc."},{"issue":"25","key":"10.1016\/j.phrs.2022.106342_bib102","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.121.055654","article-title":"Effect of long-term marine -3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis","volume":"144","author":"Gencer","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib103","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ijcard.2013.03.053","article-title":"Effects of high dose intravenous fish oil on human atrial electrophysiology: implications for possible anti- and pro-arrhythmic mechanisms in atrial fibrillation","volume":"168","author":"Kumar","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106342_bib104","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCRESAHA.114.302226","article-title":"Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression","volume":"114","author":"Heijman","year":"2014","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10840-018-0315-5","article-title":"N-3 polyunsaturated fatty acids for prevention of postoperative atrial fibrillation: updated meta-analysis and systematic review","volume":"51","author":"Wang","year":"2018","journal-title":"J. Interv. Cardiac Electrophysiol."},{"issue":"1 Pt B","key":"10.1016\/j.phrs.2022.106342_bib106","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbamem.2014.04.020","article-title":"How polyunsaturated fatty acids modify molecular organization in membranes: insight from NMR studies of model systems","volume":"1848","author":"Shaikh","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bpj.2012.06.016","article-title":"Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains","volume":"103","author":"Williams","year":"2012","journal-title":"Biophys. J."},{"issue":"21","key":"10.1016\/j.phrs.2022.106342_bib108","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1021\/ja068856c","article-title":"Docosahexaenoyl chains isomerize on the sub-nanosecond time scale","volume":"129","author":"Soubias","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2022.106342_bib109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chemphyslip.2018.01.002","article-title":"Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction","volume":"212","author":"Sherratt","year":"2018","journal-title":"Chem. Phys. Lipids"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FJC.0000000000000379","article-title":"Eicosapentaenoic acid inhibits oxidation of apob-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents","volume":"68","author":"Mason","year":"2016","journal-title":"J. Cardiovasc. Pharm."},{"issue":"24","key":"10.1016\/j.phrs.2022.106342_bib111","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1093\/eurheartj\/ehaa505","article-title":"Cholesterol crystals and atherosclerosis","volume":"41","author":"Baumer","year":"2020","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.phrs.2022.106342_bib112","first-page":"389","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"Back","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"30","key":"10.1016\/j.phrs.2022.106342_bib113","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1073\/pnas.1803119115","article-title":"Two polymorphic cholesterol monohydrate crystal structures form in macrophage culture models of atherosclerosis","volume":"115","author":"Varsano","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.phrs.2022.106342_bib114","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.bpj.2021.04.009","article-title":"EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol","volume":"120","author":"Jacobs","year":"2021","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1529\/biophysj.107.123612","article-title":"Docosahexaenoic acid enhances segregation of lipids between: 2H NMR study","volume":"95","author":"Soni","year":"2008","journal-title":"Biophys. J."},{"issue":"12","key":"10.1016\/j.phrs.2022.106342_bib116","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.bbamem.2016.10.002","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"1858","author":"Mason","year":"2016","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.phrs.2022.106342_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155161","article-title":"Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction","volume":"130","author":"Mason","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2022.106342_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100106","article-title":"EPA and DHA containing phospholipids have contrasting effects on membrane structure","volume":"62","author":"Sherratt","year":"2021","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/j.phrs.2022.106342_bib119","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/ATVBAHA.119.313093","article-title":"Preferential incorporation of administered eicosapentaenoic acid into thin-cap atherosclerotic plaques","volume":"39","author":"Sato","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib120","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2010.05.022","article-title":"Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability","volume":"212","author":"Cawood","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib121","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1253\/circj.CJ-17-0294","article-title":"Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties","volume":"82","author":"Tanaka","year":"2018","journal-title":"Circ. J."},{"key":"10.1016\/j.phrs.2022.106342_bib122","doi-asserted-by":"crossref","unstructured":"C.R. Sirtori, A. Corsini, M. Ruscica, The Role of High-Density Lipoprotein Cholesterol in 2022, Curr Atheroscler Rep (2022).","DOI":"10.1007\/s11883-022-01012-y"},{"issue":"11","key":"10.1016\/j.phrs.2022.106342_bib123","article-title":"Eicosapentaenoic acid membrane incorporation stimulates ABCA1-mediated cholesterol efflux from human THP-1 macrophages","volume":"1866","author":"Dakroub","year":"2021","journal-title":"Biochim Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.phrs.2022.106342_bib124","article-title":"Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability","volume":"173","author":"Sherratt","year":"2021","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"issue":"13","key":"10.1016\/j.phrs.2022.106342_bib125","first-page":"2525","article-title":"Inflammation during the life cycle of the atherosclerotic plaque","volume":"117","author":"Libby","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2022.106342_bib126","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pcad.2021.06.010","article-title":"P. International Lipid Expert, E. International Lipid Expert Panel, Impact of nutraceuticals on markers of systemic inflammation: potential relevance to cardiovascular diseases - a position paper from the International Lipid Expert Panel (ILEP)","volume":"67","author":"Ruscica","year":"2021","journal-title":"Prog. Cardiovasc Dis."},{"issue":"8","key":"10.1016\/j.phrs.2022.106342_bib127","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1194\/jlr.R057588","article-title":"Cytosolic phospholipase A(2): physiological function and role in disease","volume":"56","author":"Leslie","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2022.106342_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100113","article-title":"Omega-3 versus Omega-6 fatty acid availability is controlled by hydrophobic site geometries of phospholipase A2s","volume":"62","author":"Hayashi","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2022.106342_bib129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.plefa.2018.03.004","article-title":"Omega-6 fatty acids and inflammation","volume":"132","author":"Innes","year":"2018","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/JCI200113416","article-title":"Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes","volume":"108","author":"Tilley","year":"2001","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib131","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3945\/ajcn.112.041343","article-title":"Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish","volume":"96","author":"Browning","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib132","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 fatty acids and inflammatory processes: from molecules to man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochem. Soc. Trans."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib133","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbalip.2014.08.010","article-title":"Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance","volume":"1851","author":"Calder","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib134","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ajcn\/83.2.331","article-title":"Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men","volume":"83","author":"Rees","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"issue":"10","key":"10.1016\/j.phrs.2022.106342_bib135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199009063231006","article-title":"Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases","volume":"323","author":"Lewis","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib136","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0021-9258(17)43363-1","article-title":"Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product","volume":"259","author":"Lee","year":"1984","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib137","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jn\/121.4.547","article-title":"Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women","volume":"121","author":"Meydani","year":"1991","journal-title":"J. Nutr."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib138","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ajcn\/78.3.376","article-title":"Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation","volume":"78","author":"Trebble","year":"2003","journal-title":"Am. J. Clin. Nutr."},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib139","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3945\/ajcn.116.131896","article-title":"A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing EPA to DHA (ComparED) study","volume":"104","author":"Allaire","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.phrs.2022.106342_bib140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2021.03.003","article-title":"Omega-3 fatty acids ameliorate vascular inflammation: a rationale for their atheroprotective effects","volume":"324","author":"Pisaniello","year":"2021","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib141","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00380-014-0526-3","article-title":"Effect of purified eicosapentaenoic acid on red cell distribution width in patients with ischemic heart disease","volume":"30","author":"Takahashi","year":"2015","journal-title":"Heart Vessels"},{"issue":"6","key":"10.1016\/j.phrs.2022.106342_bib142","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1194\/jlr.P093013","article-title":"n-3 PUFAs improve erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial","volume":"60","author":"Meital","year":"2019","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib143","doi-asserted-by":"crossref","first-page":"L84","DOI":"10.1152\/ajplung.00077.2002","article-title":"NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription","volume":"284","author":"Novak","year":"2003","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106342_bib144","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-kappaB: a key role in inflammatory diseases","volume":"107","author":"Tak","year":"2001","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib145","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbi.2010.09.012","article-title":"Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1\/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis","volume":"25","author":"Kong","year":"2011","journal-title":"Brain Behav. Immun."},{"issue":"9","key":"10.1016\/j.phrs.2022.106342_bib146","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.94.9.4318","article-title":"Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma","volume":"94","author":"Kliewer","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.phrs.2022.106342_bib147","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2362.1993.tb01286.x","article-title":"Fraudulent (and non fraudulent) fatty acids for human health","volume":"23","author":"Sirtori","year":"1993","journal-title":"Eur. J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.phrs.2022.106342_bib148","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00229469","article-title":"Omega-3 fatty acids and the peroxisome","volume":"165","author":"Masters","year":"1996","journal-title":"Mol. Cell Biochem."},{"issue":"11","key":"10.1016\/j.phrs.2022.106342_bib149","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3945\/jn.110.125732","article-title":"Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation","volume":"140","author":"Kalupahana","year":"2010","journal-title":"J. Nutr."},{"issue":"8","key":"10.1016\/j.phrs.2022.106342_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102909","article-title":"Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired beta-cell function","volume":"24","author":"Al Rijjal","year":"2021","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.phrs.2022.106342_bib151","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.coph.2013.05.012","article-title":"Resolution phase lipid mediators of inflammation: agonists of resolution","volume":"13","author":"Serhan","year":"2013","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.phrs.2022.106342_bib152","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2015.11.002","article-title":"Docosapentaenoic acid derived metabolites and mediators - the new world of lipid mediator medicine in a nutshell","volume":"785","author":"Weylandt","year":"2016","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2022.106342_bib153","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev.pathmechdis.3.121806.151409","article-title":"Anti-inflammatory and proresolving lipid mediators","volume":"3","author":"Serhan","year":"2008","journal-title":"Annu Rev. Pathol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106342_bib154","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2022.106342_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105340","article-title":"Receptors for pro-resolving mediators as a therapeutic tool for smooth muscle remodeling-associated disorders","volume":"164","author":"Livshits","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106342_bib156","doi-asserted-by":"crossref","first-page":"12859","DOI":"10.1038\/ncomms12859","article-title":"An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques","volume":"7","author":"Fredman","year":"2016","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2022.106342_bib157","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1172\/JCI97950","article-title":"The role of non-resolving inflammation in atherosclerosis","volume":"128","author":"Kasikara","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"7503","key":"10.1016\/j.phrs.2022.106342_bib158","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106342_bib159","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.plefa.2017.08.007","article-title":"Circulating inflammation-resolving lipid mediators RvD1 and DHA are decreased in patients with acutely symptomatic carotid disease","volume":"125","author":"Bazan","year":"2017","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"issue":"9","key":"10.1016\/j.phrs.2022.106342_bib160","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/2047487317694464","article-title":"Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: a novel biomarker of non-resolving vascular inflammation, Eur","volume":"24","author":"Thul","year":"2017","journal-title":"J. Prev. Cardiol."},{"issue":"24","key":"10.1016\/j.phrs.2022.106342_bib161","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142883","article-title":"The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection","volume":"131","author":"Arnardottir","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.phrs.2022.106342_bib162","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"47","key":"10.1016\/j.phrs.2022.106342_bib163","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1093\/eurheartj\/ehab438","article-title":"The changing nature of atherosclerosis: what we thought we knew, what we think we know, and what we have to learn","volume":"42","author":"Libby","year":"2021","journal-title":"Eur. Heart J."},{"issue":"47","key":"10.1016\/j.phrs.2022.106342_bib164","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies \u2013 a consensus statement from the European atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106342_bib165","article-title":"A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes","volume":"182","author":"Sherratt","year":"2022","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"issue":"5","key":"10.1016\/j.phrs.2022.106342_bib166","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacc.2020.11.060","article-title":"Cardiovascular impact of nutritional supplementation with omega-3 fatty acids: JACC focus seminar","volume":"77","author":"Weinberg","year":"2021","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:42:02Z","timestamp":1760913722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822002870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":166,"alternative-id":["S1043661822002870"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106342","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omega-3 and cardiovascular prevention \u2013 Is this still a choice?","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106342"}}